Lung cancer survival has improved across the Nordic countries, but important differences remain. NORDCAN data show clear gains in 5-year age-standardised relative survival between 2004–2008 and 2019–2023 in Denmark, Finland, Iceland, Norway, and Sweden. However, the magnitude of improvement differs between countries and between males and females.
These differences raise important research questions for Nordic lung cancer care. How much of the improvement is related to earlier diagnosis, standardized diagnostic pathways, multidisciplinary care, treatment access, radiotherapy and surgery, molecular testing, immunotherapy, registry-based quality monitoring, or broader healthcare system factors?
Why quality registries matter
The Nordic countries have a long tradition of population-based cancer registration. These registries provide a foundation for monitoring incidence, treatment patterns, survival, and variation in care. Lung cancer quality registries and national cancer registries can help identify whether patients are diagnosed early enough, receive appropriate staging, are discussed in multidisciplinary team meetings, and have access to guideline-based treatment.
Registry-based research also shows that Nordic lung cancer data are not identical across countries. Differences in registry structure, available variables, completeness, cause-of-death linkage, and survival measures mean that careful harmonisation is needed before drawing conclusions from direct comparisons.
Standardized care pathways and timelines
Standardized cancer pathways aim to reduce delays, clarify responsibilities, and create more predictable diagnostic and treatment processes for patients with suspected lung cancer. Denmark was the first Nordic country to implement a lung cancer pathway in 2009. Norway followed with standardized cancer patient pathways in 2015, and Sweden implemented standardized cancer pathways between 2015 and 2018, including lung cancer pathways.
Finland has more recently strengthened its national approach through FICAN’s first common national cancer strategy and the Finnish Lung Cancer Programme. The Finnish standardized lung cancer care path defines key steps from referral and imaging to staging, pathological diagnosis, molecular testing, multidisciplinary treatment planning, treatment initiation, rehabilitation, smoking cessation, and palliative support.
Finland: quality reporting and care pathway development
The Finnish lung cancer quality report for 2019–2023 highlights regional variation in diagnosis, late-stage detection, limited availability of clinical stage information, and challenges in data completeness. These findings underline the need for earlier diagnosis, more complete clinical data, and harmonised care pathways across Finnish wellbeing services counties.
The report is part of a broader national effort to improve cancer care quality and equity. FICAN’s national strategy for 2024–2026 aims to support high-quality and equitable cancer care across the full cancer pathway, from early detection to treatment and comprehensive support.
What may explain Nordic survival differences?
A comparative Nordic study by Khalife and colleagues suggests that survival differences may not be explained only by specialist lung cancer care. The study identified several potential system-level factors, including differences in primary care resources, waiting times in primary care, access to CT imaging from primary care, availability of novel treatments, and whether hospitals track lung cancer survival and mortality outcomes.
These findings suggest that improving lung cancer outcomes requires attention to the whole pathway: symptom recognition, primary care access, diagnostic imaging, referral processes, staging, multidisciplinary discussion, treatment availability, and outcome monitoring.
Nordic learning opportunities
Nordic collaboration offers an important opportunity to learn from differences between healthcare systems. Countries with earlier implementation of standardized pathways and more mature quality registries may provide lessons for pathway design, data capture, benchmarking, and quality improvement. At the same time, Finland’s current work on national strategy, quality reporting, and standardized care pathways provides a timely example of how registry findings can be translated into practical improvement.
For NTOG, this topic connects directly to key research priorities: lung cancer registries, quality indicators, multidisciplinary care, standardized pathways, early diagnosis, access to treatment, and real-world outcome research across the Nordic countries.
Key questions for future Nordic research
- How have standardized lung cancer pathways affected time to diagnosis and treatment?
- Do pathway timelines correlate with improved survival or earlier-stage diagnosis?
- How do national lung cancer quality registries differ in variables, completeness, and reporting?
- Which quality indicators best predict meaningful improvements in patient outcomes?
- How does access to CT imaging from primary care affect stage at diagnosis?
- How do multidisciplinary team meetings influence treatment decisions and equity of care?
- How can Nordic countries harmonise registry data to support fair comparisons?
Continued Nordic collaboration can help turn these questions into shared research, better data, and practical improvements in lung cancer care.